Linda T. Vahdat, MD, MBA, discusses the rationale for depleting copper levels as a form of high-risk triple-negative breast cancer management.
Back
Dr Vahdat on the Potential for Copper Depletion in High-Risk TNBC Management
Dr Vahdat on the Potential for Copper Depletion in High-Risk TNBC Management
Episodes
All
All
Linda T. Vahdat, MD, MBA, discusses the scientific rationale for therapeutic copper depletion to prevent triple-negative breast cancer metastasis.
Linda T. Vahdat, MD, MBA, discusses the design of a phase 2 trial of copper depletion as a strategy to prevent metastasis in high-risk TNBC.
Advertisement
Advertisement
Trending on OncLive
1
Dive into the Data Supporting the FDA Approval of Iberdomide Plus Daratumumab/Dexamethasone in R/R Myeloma
2
T-DXd Improves PFS in First-Line HER2-Mutant NSCLC
3
Five Under 5: Top Oncology Videos for the Week of 8/9
4
FDA Grants Fast Track Designation to Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
5